“Solos is putting added emphasis on its MammoView line of breast endoscopy instrumentation by developing new instruments which will include a new biopsy device to complement its existing line and is in the process of obtaining the necessary regulatory approvals to broaden our markets,” said Bob Segersten, president of Solos Endoscopy, in the release.
The company intends to market MammoView and its components to hospitals across the country and internationally.
Solos Endoscopy instruments are FDA approved. The company expects to receive the CE mark for its entire instrument line and will then market MammoView within countries that recognize the CE mark.
Related Articles on Solos Endoscopy:
Solos Endoscopy Reports 16% Sales Increase
Solos Endoscopy Reports Sales Increase of 16% for Q1
Solos Endoscopy to Launch New Endoscopic Instrument Line
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
